Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Pashtoon Murtaza Kasi(Cornell University), Takayuki Yoshino(University of Tsukuba), Atsushi Ohtsu(National Cancer Center Hospital East), Daisuke Kotani(National Cancer Center Hospital East), Michael Cecchini(Yale Cancer Center), Axel Grothey(Campbell Clinic), Howard S. Höchster(Rutgers, The State University of New Jersey), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States)), Kohei Shitara(National Cancer Center Hospital East)
BMC Cancer
July 13, 2016
10.1186/s12885-016-2491-y
Cited by 75

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Colorectal cancer
|The Lancet|2019|5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k